Over 400 Total Lots Up For Auction at Three Locations - Jutland 12/13, MD 12/14, CA 12/16

Xstrahl releases platform for proton, photon, carbon and flash therapy research

by John R. Fischer, Senior Reporter | August 27, 2019
Rad Oncology Proton Therapy
SARRP beamline
Xstrahl Life Science has released a new radiation platform dedicated to research around proton, photon, carbon and flash experimentation.

The Small Animal Radiation Research Platform (SARRP) beamline is the first 3D bioluminescent optical imaging modality in the industry, according to Xstrahl, and creates reproduceable images by pairing seamlessly with the beamline experiments.

"SARRP beamline has been fully designed from the top down to give best in class image guidance to beamline experiments, and gives researchers an adaptable platform to take their research beyond current capabilities," Xstrahl Group CEO Adrian Treverton told HCB News. "Using an on-board high resolution cone beam-CT imaging and 3-D bioluminescent tomographic imaging, the SARRP beamline can target micro beams (down to 0.5mm) of radiation to an accuracy of 200μm."

The system is extendable with the Xstrahl MuriGlo, an advanced in vivo optical imaging system with bioluminescence (BLI), bioluminescence tomography (BLT1) and transillumination fluorescence imaging (TFI2) capabilities.

Its release comes more than one year after the launch of the company’s RADiant therapy system, which is designed with a dual modality to provide a pain-free, non-surgical alternative for treating non-melanoma skin cancers, keloids, and superficial lesions, especially ones in hard to reach or sensitive facial regions.

“If a patient is presented with a non-melanoma skin cancer, their options are usually going to be surgery or no surgery. Depending on depth of cancer, you can be left with quite a scar, which might need some attention from a plastic surgeon,” Treverton told HCB News at the time. “What our system will do is [deliver] radiation that knocks out the cancer cells, which are less radioresistant than normal tissue. It actually means that the patient will heal up without any scarring at all. Physicians can remove keloids and deliver radiation that stops the keloids from growing back.”

X-strahl develops, manufactures and supplies systems for preclinical radiation research.

You Must Be Logged In To Post A Comment